Amira Pharmaceuticals to Present Preclinical, Clinical Data from DP2 Receptor Antagonist Program at Pacifichem 2010

By Amira Pharmaceuticals Inc., PRNE
Monday, December 13, 2010

SAN DIEGO, December 14, 2010 - Amira Pharmaceuticals, Inc. announced today that it will present
preclinical and clinical data from its DP2 receptor antagonist program on
December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from
Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D.,
in a presentation titled "Discovery and optimization of a novel series of DP2
antagonists with efficacy in mouse models of COPD and asthma."

"We are very excited about the two structurally distinct clinical stage
molecules, AM211 and AM461," said Peppi Prasit, Ph.D., Chief Scientific
Officer. "In particular, the safety and pharmacodynamic readouts displayed by
these compounds allowed us to investigate doses that ranged all the way to
complete inhibition of the receptor at trough plasma concentrations."

The DP2 receptor is part of the Arachidonic Acid pathway and is also
known as CRTH2, or chemoattractant receptor-homologous molecule expressed in
Th2 lymphocytes. DP2 is a high affinity receptor for the prostaglandin D2 and
in humans is implicated in Th2-dependent allergic inflammation.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is
a small molecule pharmaceutical company focused on the discovery and
development of new drugs to treat inflammatory disease. Our discovery team is
building on unparalleled insights into bioactive lipid pathways and complex
signaling processes controlling many conditions including asthma, chronic
obstructive pulmonary disease, fibrotic diseases and cancer. Amira combines
the rigor of a big pharmaceutical company with the ingenuity and energy of a
small company, creating an environment for efficient development of novel
compounds and effective pre-clinical and clinical program decisions. Amira
has a partnership with GlaxoSmithKline for the development of FLAP
(5-lipoxygenase activating protein) inhibitors in respiratory and
cardiovascular disease. For more information, visit

Ian Stone of Russo Partners, +1-619-528-2220, ian.stone at, for Amira Pharmaceuticals, Inc.

will not be displayed